About the Author

Dr. Guimarães is a research scientist and analyst at the Ezequiel Dias Foundation. Her research interests and work include the molecular diagnosis and sequencing of SARS-CoV-2, monkeypox virus, and arboviruses, including dengue, Zika, chikungunya, and yellow fever viruses, and other pathogens of importance to public health.

References


Address for correspondence: Felipe Campos de Melo Iani, Ezequiel Dias Foundation, Rua Conde Pereira Carneiro, 80—Gameleira, Belo Horizonte 30510-010, Brazil; email: felipe.iani@funed.mg.gov.br

Antimicrobial-Resistant Infections after Turkey/Syria Earthquakes, 2023

Anthony Rizk, Antoine Abou Fayad, Louis-Patrick Haraoui

Author affiliations: Geneva Graduate Institute, Geneva, Switzerland (A. Rizk); American University of Beirut, Beirut, Lebanon (A. Abou Fayad); Université de Sherbrooke, Sherbrooke, Québec, Canada (L.-P. Haraoui)

DOI: https://doi.org/10.3201/eid2906.230316

The 2023 earthquakes that affected Turkey and Syria, with Kahramanmaras Province in Turkey at their epicenter, measured 7.8 and 7.5 on the Richter scale. The effects were devastating, making these the strongest earthquakes in Turkey since 1939. Combined with their multiple aftershocks, the earthquakes caused >50,000 deaths and severely damaged or collapsed >170,000 buildings (https://www.aljazeera.com/news/2023/2/25/death-toll-climbs-above-50000-after-turkey-syria-earthquakes). In their wake, the earthquakes left a growing humanitarian crisis. If previous experiences are any indication, we can also expect hospitals caring for the injured and wounded to struggle with highly antimicrobial-resistant infections, many of which will lead to excess illnesses and deaths.

Multidrug resistant microbes have often been reported after earthquakes and other natural disasters. Medical literature on earthquake-associated injuries, going as far back as the Marmara, Turkey, earthquake of 1999 (1), have consistently shown highly resistant microbial strains emerging in hospital settings and causing hospital-acquired infections in trauma patients. Antimicrobial-resistant Acinetobacter baumannii has been identified in disproportionately high rates from infections associated with large-scale earthquakes in Southeast Asia in 2004; northern Pakistan in 2005; Wenchuan, China, in 2008; central Italy in 2009; and Haiti in 2010 (Appendix, https://wwwnc.cdc.gov/EID/article/29/6/23-0316-App1.pdf).
Although earthquake-associated pathogens detected in hospital settings have been consistently multidrug resistant, their resistance profiles have varied. The etiology of antimicrobial resistance from earthquakes remains uncertain. After the Marmara earthquake of 1999, associated earthquakes remains uncertain. After the Marmara earthquake, patients with multiple wounds admitted to the intensive care unit of the Cologne-Merheim Medical Center in Germany were reportedly contaminated with multidrug-resistant A. baumannii, extended-spectrum β-lactamase Escherichia coli, and methicillin-resistant Staphylococcus aureus (2). After the 2005 northern Pakistan earthquake, Kiani et al. reported emergence of multiply drug-resistant Acinetobacter spp., Enterobacter spp., and other gram-negative organisms, susceptible to amikacin only. Hospitals were overwhelmed with staff and antimicrobial drug shortages, and wounds were often treated empirically because of limited laboratory capacities (3). After the 2008 earthquake in Wenchuan, China, the predominant pathogen causing infections was A. baumannii; 1 hospital reported that >65% of Acinetobacter isolates were resistant to a wide range of antimicrobial drugs, except imipenem, and 24.6% of isolates were pan-drug resistant (4).

Since the 2023 Turkey/Syria earthquakes, multidrug resistance has not yet been reported. However, on the basis of the epidemiology of infections in earthquake-stricken regions, we expect hospitals in the region to struggle with containing nosocomial transmission of highly resistant pathogens that may increase deaths among hospitalized patients. Also of concern is the re-emergence of other infectious diseases, such as cholera, known to be precipitated by disaster settings (5). The Turkey/Syria earthquakes come on the heels of multiple crises in the region, many of which have been shown to influence the rising rates of multidrug resistance, as in the wake of the Iraq and Syrian conflicts (6). Rising rates of antimicrobial resistance are further compounded by the regionwide travel of wounded patients for treatment as healthcare infrastructure in Iraq and Syria collapsed (7). Medicine shortages, especially resulting from sanctions in Syria and Iraq and following the 2019 financial collapse in Lebanon, further compound selective pressures on microbes to develop specific resistance profiles.

Hospitals in and outside the region treating injuries from the Turkey/Syria earthquakes will probably observe a surge in highly resistant pathogens and nosocomial transmission. In addition to providing immediate care for the injured and displaced, relief efforts should therefore anticipate a probable increase in antimicrobial-resistant infections for which therapeutic options may be limited. Detecting and responding to this superimposed crisis urgently requires support and expansion of existing microbiology laboratory capacity. Recent initiatives, such as the deployment of telemicrobiology in northern Syria, are examples of how to rapidly assist local laboratory teams in settings of social disruption (8). Training healthcare workers on surgical techniques and wound care adapted to deal with traumatic injuries have also been shown to enhance wound healing and to limit complications such as chronic and recurrent skin and soft tissue infections, which are risk factors for antimicrobial resistance (9). Early-stage detection and aggressive infection-control practices (e.g., active surveillance, contact isolation, sampling of healthcare workers and hospital environments, and antimicrobial stewardship) during and after disasters play key roles in preventing resistant strains from becoming endemic to healthcare facilities (10). Healthcare facilities may need to consider patient decolonization through chlorhexidine bathing to forestall colonization by antimicrobial-resistant Acinetobacter strains (10). Communities affected by the recent earthquakes will probably experience their effects for months to come. It is not too late to act to prevent further complications from these natural disasters, such as antimicrobial-resistant infections, from compounding ongoing human tragedies.

This work was supported by the New Frontiers in Research Fund, Canada (NFRFE-2019-00444) (A.R. and L.-P.H.), the Fonds de Recherche du Quebec-Sante (282182) (L.-P.H.), and the Canadian Institute for Advanced Research (GS-0000000256) (L.-P.H.).

About the Author
Mr. Rizk is a PhD candidate in anthropology at the Geneva Graduate Institute, Switzerland. His research interests include scientific laboratory capacities and antimicrobial resistance.

References
3. Kiani QH, Amir M, Ghazanfar MA, Iqbal M. Microbiology of wound infections among hospitalised patients following
Detection of Severe Murine Typhus by Nanopore Targeted Sequencing, China

Panpan Qian, Xiaohua He, Mei Yang, Li Wei, Lihui Zhang, Xiqian Xing

Authors affiliation: The Affiliated Hospital of Yunnan University, Kunming, China

DOI: https://doi.org/10.3201/eid2906.221929

We report a case of murine typhus in China caused by Rickettsia typhi and diagnosed by nanopore targeted sequencing of a bronchoalveolar lavage fluid sample. This case highlights that nanopore targeted sequencing can effectively detect clinically unexplained infections and be especially useful for detecting infections in patients without typical signs and symptoms.

Murine typhus is caused by Rickettsia typhi bacteria transmitted by rat or cat flea vectors. Persons with murine typhus often have nonspecific or mild symptoms, such as fever, myalgia, and rash. In rare instances, murine typhus will cause atypical or multiple organ dysfunction syndrome (MODS) (1,2).

Murine typhus is an undifferentiated febrile illness, which makes it challenging to recognize and diagnose. We report a case of murine typhus and MODS in a patient without rash. We diagnosed murine typhus by using nanopore targeted sequencing (NTS) of a bronchoalveolar lavage fluid (BALF) sample, aiming to provide more reference for clinical practice.

A 60-year-old female farmer from Yunnan Province, China, had fatigue, anorexia, nausea, dizziness, and vomiting for 1 week. At admission, she was afebrile and hemodynamically stable and did not have headache, rash, or eschar. Chest computed tomography (CT) imaging showed pneumonia and a small plural effusion (Figure, panels A, B). By the next day, her condition had deteriorated. She experienced chills, fever (temperature 39°C), severe hypotension (70/53 mm Hg), dyspnea, and deterioration of the oxygenation index. Preliminary laboratory investigation demonstrated mild leukocytosis (13.86 × 10^9/L), moderately elevated transaminase levels (alanine aminotransferase 197 U/L, aspartate aminotransferase 128 U/L), severe thrombocytopenia (12 × 10^9/L), coagulation disorder (D-dimer 49.8 µg/mL), elevated C-reactive protein (207.4 mg/L) and procalcitonin (4.65 ng/mL) levels, and respiratory failure (partial pressure of oxygen 58.9 mm Hg).

The patient was given intravenous meropenem and norepinephrine and was admitted on noninvasive ventilation. We then conducted tests for malaria, Legionella, influenza virus, SARS-CoV-2, HIV, herpes simplex virus, cytomegalovirus, Epstein-Barr virus IgM, Roxiella burnetti IgM (phase II antigen), R. typhi IgM, Mycoplasma pneumoniae IgM, Chlamydia IgM, respiratory syncytial virus IgM, and adenovirus IgM; results were all negative. In addition, testing of blood, urine, stool, and sputum cultures and bone marrow biopsy all produced negative results.

On admission day 5, she remained normotensive. Her body temperature dropped, but she still had a low-grade fever, body temperature fluctuating from 37.5°C to 38°C. However, the cause of her severe infection remained unclear. The next day, she underwent bronchoscopy. BALF was sent to undergo NTS analysis to Wuhan Dgensee Clinical Laboratory Co., Ltd (https://www.dgensee.com). Two days later, NTS results revealed R. typhi DNA.

Address for correspondence: Louis-Patrick Haraoui, Hôpital Charles-Le Moyne, Casier 251, 3120 Blvd Taschereau, Greenfield Park, QC J4V 2H1, Canada; email: louis.patrick.haraoui@usherbrooke.ca